Breaking: FDA Greenlights Profound Medical's TULSA AI Module
- September 26th, 2023
- 389 views
Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, including cancer and benign prostatic hyperplasia (BPH).
The Thermal Boost module, Profound's first FDA-cleared TULSA AI module, enables surgeons to temporarily increase the ablation target temperature in areas where advanced-stage cancer might be present, improving confidence in effective cancer cell ablation.
$PROF was trading at $10.94 in the extended session, up $1.04 (+10.51%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login